A multicenter, prospective study of C2-monitored cyclosporine microemulsion in a U.S. population of de novo renal transplant recipients

Transplantation

Volumn 80, Issue 7, 2005, Pages 910-916

  Vincenti, Flavio ^a,p   Mendez, Robert ^b   Curtis, John ^c   Light, Jimmy ^d   Pearson, Thomas ^e   Wu, You Min ^f   Katz, Stephen M ^g   Akalin, Enver ^h   Esterl, Robert ⁱ   Gugliuzza, Kristene ^j   Shihab, Fuad ^k   Jordan, Stanley ^l   Jonsson, Johann ^m   Molmenti, Ernesto ⁿ   Barbeito, Ralph ^o  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b National Institute of Transplantation Los Angeles   (United States)

^c University of Alabama at Birmingham   (United States)

^d WASHINGTON HOSPITAL CENTER   (United States)

^e EMORY UNIVERSITY   (United States)

^f UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^g UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^h MOUNT SINAI HOSPITAL   (United States)

ⁱ UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^j UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^k UNIVERSITY OF UTAH   (United States)

^l CEDARS SINAI MEDICAL CENTER   (United States)

^m INOVA FAIRFAX HOSPITAL   (United States)

ⁿ JOHNS HOPKINS HOSPITAL   (United States)

^o NOVARTIS PHARMA AG   (Switzerland)

^p UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

C2; Cyclosporine; Kidney transplantation; Rejection

Indexed keywords

BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CREATININE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; AFRICAN AMERICAN; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEATH; DOSE RESPONSE; DRUG EFFICACY; DRUG EXPOSURE; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GINGIVA HYPERPLASIA; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; HIRSUTISM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MICROEMULSION; MULTICENTER STUDY; OUTCOMES RESEARCH; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; SIDE EFFECT; UNITED STATES;

AFRICAN AMERICANS; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; EMULSIONS; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, ACUTE; KIDNEY TRANSPLANTATION; MALE; POPULATION; UNITED STATES;

EID: 27644524494     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000173802.70980.50     Document Type: Article

References (26)

1. Lindholm A, Kahan BD. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcomes after kidney transplantation. Clin Pharmacol Ther 1993; 54: 205.
2. Keown P, Landsberg D, Halloran P, et al. A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Report of the Canadian Neoral Renal Transplantation Study Group. Transplantation 1996; 62: 1744.
3. Amante AJ, Kahan BD. Abbreviated AUC strategy for monitoring cyclosporine microemulsion therapy in the immediate posttransplant period. Transplant Proc 1996; 28: 2162.
4. Nashan B, Cole E, Levy G, Thervet E. Clinical validation studies of neoral C2 monitoring: A review. Transplantation 2002; 73: S3.
5. Jorga A, Holt DW, Johnston A. Therapeutic drug monitoring of cyclosporine. Transplant Proc 2004; 36 (Suppl2S): 396S.
6. Mahalati K, Belitsky P, Sketris I, et al. Neoral monitoring by simplified sparse sampling area under the concentration-time curve: Its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation 1999; 68: 55.
7. Mahalati K, Belitsky P, West K, et al. Approaching the therapeutic window for cyclosporine in kidney transplantation: A prospective study. J Am Soc Nephrol 2001; 12: 828.
8. Canadian Neoral Renal Transplantation Study Group. Absorption profiling of cyclosprine microemulsion (Neoral) during the first 2 weeks after renal transplantation. Transplantation 2001; 72: 1024.
9. Pescovitz MD, Barbeito R. Two-hour post-dose cyclosporine level is a better predictor than trough level of acute rejection of renal allografts. Clin Transplant 2002; 16: 378.
10. 2 monitoring of cyclosporine microemulsion (Neoral). Transplantation 2003; 76: 903.
11. Levy G, Burra P, Cavallari A, et al. Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-hr post-dose levels (C2). Transplantation 2002; 73: 953.
12. Kahan BD. Therapeutic drug monitoring of cyclosporine: 20 years of progress. Transplant Proc 2004; 36 (Suppl2S): 378S.
13. Levy G. C2 monitoring strategy for optimizing cyclosporine immunosuppression form the Neoral formulation. Biodrugs 2001; 15: 279.
14. Nashan B, Cole E, Levy G, Thervet E. Clinical validation studies of Neoral C2 monitoring: A review. Transplantation 2002; 73: S3.
15. Levy G, Thervet E, Lake J, Kazuharu U. Patient management of Neoral C2 monitoring: An international consensus statement. Transplantation 2002; 73: S12.
16. Cole E, Karsten M, Johnston A, et al. Recommendations for the implementation of Neoral C2 monitoring in clinical practice. Transplantation 2002; 73: S19.
17. Nankivell BJ, Gruenewald SM, Allen R, Chapman JR. Predicting Glomerular filtration rate after kidney transplantation. Transplantation 1995; 59: 1683.
18. Kovarik JM, Mueller EA, Richard F, et al. Evidence for earlier stabilization of cyclosporine pharmacokinetics in de novo renal transplant patients receiving a microemulsion formulation. Transplantation 1996; 62: 759.
19. International Neoral Renal Transplantation Study Group. Randomized, international study of Neoral absorption profiling in renal transplantation with basiliximab immunoprophylaxis. Am J Transplant 2002, 2: 157.
20. Felipe CR, Silva HT Jr, Machado PG, et al. Time-dependent changes in cyclosporine exposure: implications for achieving target concentrations. Transp Int 2003; 16: 494.
21. Birsan T, Loinig C, Bodingbauer M, et al. Comparison between C0 and C2 monitoring in de novo renal transplant recipients: A retrospective analysis of a single-center experience. Transplantation 2004; 78: 1787.
22. Adu D, Cockwell P, Ives NJ, et al. Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomized trials. Br Med J 2003; 326: 789.
23. Keown PA, Balshaw R, Khorasheh S, et al. Meta-analysis of basiliximab for immunoprophylaxis in renal transplantation. Biodrugs 2003; 17: 271.
24. Webster AC, Playford EG, Higgins G, et al. Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials 1. Transplantation 2004; 77: 166.
25. Balbontin B, Kiberd B, Singh A, et al. Basilbdmab widens the therapeutic window for AUC-monitored Neoral therapy early after kidney transplantation. Transplant Proc 2003; 35: 2409.
26. Johnston A, David OJ, Cooney GF. Pharmacokinetic validation of Neoral absorption profiling. Transplant Proc 2000; 32 (Suppl3A): 53S.